Tumor Immunology (TIM) Research Program

总结 肿瘤免疫学项目（TIM）的使命是团结那些共同致力于 协同工作，以促进我们对癌症和免疫系统之间关系的理解， 并开发创新和有效的免疫疗法。TIM的首要目标是阐明 免疫系统和癌细胞之间相互作用的机制，为免疫系统和癌细胞之间的相互作用提供了理论基础。 设计更有效的癌症治疗方法。TIM调查员在三个级别开展工作： 研究调查调节对癌症的免疫反应的细胞和分子机制，（ii） 转化研究有助于将基本发现转化为治疗方法，并在适当的环境中测试这些治疗方法。 临床前模型，以及（iii）设计和执行测试新型免疫系统的临床试验的临床研究。 基于癌症疫苗或创新的免疫疗法。研究围绕3个互补的 主题目的：目的1：揭示抗肿瘤免疫及其逃避的基本机制，目的2： 阐明微生物群系对抗肿瘤免疫和对治疗的反应的作用，目的3：开发 TIM由30名成员组成，来自12个国家和地区， 纽约大学医学院和纽约大学牙科学院的教授。成员目前是PI 80 资助癌症相关项目，每年提供1170万美元的直接成本（250万美元的NCI）。在融资期间 在此期间，TIM成员负责癌症免疫学的范式转移基础研究发现， 还进行了几项改变实践的随机临床试验。TIM研究导致了 几种新的基于免疫的疗法，TIM医生成员累计689名患者接受免疫治疗 过去六年的研究。值得注意的是，PCC也是纽约唯一开设免疫肿瘤学的机构 在一家公共安全网医院进行试验。成员还领导了许多创新的早期临床试验， 都直接来自于我们实验室的基础科学研究。自2012年以来，项目成员发布了 443篇癌症相关论文，其中许多发表在生物医学科学领域的领先期刊上（约25%发表在具有IF的期刊上 > 20）。该计划是高度互动的，例如我们的23个积极的多PI赠款和合作 出版物（12%方案内/23%方案间/29% NCI-CC间）。第187章也是 发明披露，签署了11项许可协议，并成立了3家基于免疫疗法的初创公司 企业TIM从成为PCC的一个组成部分中获益匪浅。在本周期，TIM有8名成员 从PCC获得了总计190，000美元的试点资金，这为许多富有成效的合作奠定了基础。这些， 反过来，导致了新的科学发现，创新的实验疗法的发展，成功的 临床试验的实施，以及NIH和基金会的资金总额超过240万美元， > 1100%的投资回报率。

Summary The mission of the Tumor Immunology Program (TIM) is to unite investigators who share a commitment to work collaboratively to advance our understanding of the relationship between cancer and the immune system, and develop innovative and effective immune-based therapeutics. The overarching goal of TIM is to elucidate the mechanisms of interactions between the immune system and cancer cells, providing the rationale for the design of more effective approaches to cancer treatment. TIM investigators operate at three levels: (i) Basic research investigating the cellular and molecular mechanisms that regulate the immune response to cancer, (ii) Translational research that helps transition basic findings into therapies and test these therapies in appropriate preclinical models, and (iii) Clinical research that designs and executes clinical trials testing novel immune- based cancer vaccines or innovative immunotherapies. Research is organized around 3 complementary thematic aims: Aim 1: To discover basic mechanisms regulating anti-tumor immunity and its evasion, Aim 2: To elucidate the effect of the mcirobiome on anti-tumor immunity and response to therapy, Aim 3: To develop strategies to enhance the efficacy of immunotherapy.TIM is composed of 30 members, drawn from 12 departments in NYU School of Medicine and from NYU College of Dentistry. Members are currently PIs on 80 funded cancer-related projects, delivering $11.7M in annual direct costs ($2.5M NCI). During the funding period, TIM members were responsible for paradigm-shifting basic research findings in cancer immunology, and also conducted several practice-changing randomized clinical trials. TIM research led to the design of several new immune-based therapeutics, and TIM physician members accrued 689 patients to immunotherapy studies over the past 6 years. Of note, PCC is also the only institution in New York to open immuno-oncology trials at a public safety net hospital. Members also lead many innovative early phase clinical trials that emanated directly from basic science research in our laboratories. Since 2012, program members published 443 cancer-related papers, many in the leading venues in biomedical science (~25% were in journals with IF >20). The program is highly interactive, as exemplified by our 23 active multi-PI grants and collaborative publications (12% intra-programmatic/23% inter-programmatic/29% inter-NCI-CC). TIM members also filed 187 invention disclosures, signed 11 license agreements, and founded 3 immunotherapy-based start-up companies. TIM derives great benefit from being an integral part of PCC. In the current cycle, 8 TIM members received pilot funding from PCC totaling $190,000, which seeded numerous productive collaborations. These, in turn, led to novel scientific discoveries, development of innovative experimental therapeutics, successful clinical trial implementation, and NIH and foundation funding totaling more than $2.4 million dollars for a >1100% return on investment.